Novacyt

Novacyt is an Anglo-French biotechnology group specializing in molecular diagnostics, providing an extensive portfolio of technologies and services geared towards genomic medicine. The company was established in July 2006 by Jean-Pierre Crinelli, who brought with him approximately 30 years of experience in the automotive and electrical components industries, focusing on M&A and business restructuring. Publicly listed on the London Stock Exchange's AIM market (NCYT) and the Euronext Growth in Paris (ALNOV), the company has strategically expanded its capabilities and market reach through key acquisitions. A significant milestone was the acquisition of Yourgene Health in September 2023 for £16.7 million, a move that diversified its portfolio and scaled its operations, particularly in reproductive health.

The group operates through several business segments, including Primerdesign, Yourgene Health, and IT-IS International, generating revenue from the development, manufacture, and sale of molecular assays and instrumentation. Its business model targets multiple sectors such as human health, animal health, and environmental diagnostics, offering end-to-end solutions from sample to result. For the first half of 2024, Novacyt reported revenues of £10.3 million, with Yourgene Health contributing £7.8 million of the total. The company serves a global client base across more than 65 countries, including private laboratories, non-governmental organizations, and healthcare providers.

Novacyt's product portfolio is structured around three primary areas. The Clinical segment offers in-vitro diagnostic products for reproductive health, including non-invasive prenatal tests (NIPT), cystic fibrosis screening, and precision medicine assays like DPYD genotyping. The company gained prominence in 2020 when its Primerdesign division launched one of the first commercial molecular tests for SARS-CoV-2, which received WHO Emergency Use Listing. The Instrumentation division provides advanced DNA sample preparation platforms like the Ranger® Technology and real-time quantitative PCR (qPCR) instruments. The Research Use Only segment supplies high-performance qPCR assays and workflows to the life science industry, supporting research in human health, agriculture, and veterinary fields.

Keywords: molecular diagnostics, genomic medicine, qPCR assays, in-vitro diagnostics, reproductive health, precision medicine, infectious disease testing, NIPT, DNA sample preparation, clinical diagnostics, pathogen detection, real-time PCR, Yourgene Health, Primerdesign, CE-IVD, Ranger Technology, multiplex PCR, oncology diagnostics, cystic fibrosis screening, liquid biopsy